SCHEMBL2889485

SCHEMBL2889485

CC(C)(C)OC(=O)N(c1ccc(Cl)cc1)c1cncc(-c2ncccn2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MT-CO2 P00403 1/20 0.43
RORC P51449 1/20 0.35
LMNA P02545 2/20 0.34
SCN10A Q9Y5Y9 5/20 0.33
SCN2A Q99250 4/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
PAX8 Q06710 1/20 0.33
RAB9A P51151 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
ALDH1A1 P00352 1/20 0.33
RPLP1 P05386 1/20 0.32
RPLP0 P05388 1/20 0.32
RPS17 P08708 1/20 0.32
RPSA P08865 1/20 0.32
RPS2 P15880 1/20 0.32
RPL35A P18077 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2889310 0.89 MT-CO2 (0.42) MT-CO2RORCLMNAMEN1KMT2A
SCHEMBL2892672 0.87 MT-CO2 (0.43) MT-CO2RORCMEN1KMT2ARAB9A
SCHEMBL2889103 0.85 MT-CO2 (0.41) MT-CO2RORCSCN10ASCN2A
SCHEMBL2891573 0.84 MT-CO2 (0.43) MT-CO2RORCLMNASCN10ASCN2A
SCHEMBL3655649 0.84 RAB9A (0.36) LMNASCN10ASCN2AMEN1KMT2A
SCHEMBL2885431 0.83 MT-CO2 (0.41) MT-CO2RORCLMNAMEN1KMT2A
SCHEMBL2890838 0.83 MT-CO2 (0.49) MT-CO2RORCLMNAMEN1KMT2A
SCHEMBL2890768 0.82 MT-CO2 (0.41) MT-CO2RORC
SCHEMBL13028186 0.82 MT-CO2 (0.43) MT-CO2RORCSCN10ASCN2APAX8
SCHEMBL2889186 0.81 CNR1 (0.44) MT-CO2RORCSCN10ASCN2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415358-B2 Pyrazine derivatives and their use as potassium channel modulators NEUROSEARCH A/S (DK) 2013-04-09 US disclosed
US-8415358-B2 Pyrazine derivatives and their use as potassium channel modulators NEUROSEARCH A/S (DK) 2013-04-09 US disclosed
US-8415358-B2 Pyrazine derivatives and their use as potassium channel modulators NEUROSEARCH A/S (DK) 2013-04-09 US disclosed
US-20100286161-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2010-11-11 US disclosed
US-20100286161-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS CADENT THERAPEUTICS, INC. 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286161-A1 PYRAZINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNQ5, KCNA5 MT-CO2 2921/4885RORC 1230/4885LMNA 3236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.